This thesis examines cancer and mortality rates among people diagnosed with hepatitis B (HBV) and C (HCV) infection in New South Wales (NSW) from 1990 through 2002, by linking hepatitis notifications with the NSW Central Cancer Registry (CCR) and National Death Index. Of the 39101 HBV, 75834 HCV and 2604 HBV/HCV co-infection notifications included 1052, 1761 and 85 were linked to cancer notifications and 1233, 4008 and 186 were linked to death notifications respectively. Of 2072 hepatocellular carcinoma (HCC) notifications to the CCR 323, 267 and 85 were linked to HBV, HCV and HBV/HCV co-infection notifications. Incidence of HCC was 6.5, 4.0 and 5.9 per 1000 person years for HBV, HCV and HBV/HCV co-infected groups. Risk of HCC in those diagnosed with hepatitis was 20 to 30 times greater than the standard population. There was a marginally statistically significant increased risk of immunoproliferative malignancies associated with HCV infection (SIR=5.6 95% CI 1.8 ???17.5). Risk of death for those with hepatitis was significantly greater, 1.5 to 5 fold, than the general population with the greatest risk among those with HBV/HCV co-infection. The primary cause of HBV deaths was liver related, particularly HCC, whereas in the HCV groups drug related deaths were most frequent. Among people with HCV, risk of dying from drug related causes was significantly greater than from liver related causes (p=0.012), with the greatest increased risk in females age 15- 24 years (SMR 56.9, 95%CI 39.2???79.9). Median age at diagnosis of HCC varied markedly by country of birth and hepatitis group: HBV 66, 63 and 57years ; HCV 51, 68 and 71 years; unlinked 69, 70 and 64 years for Australian, European, and Asian-born groups, respectively (P<0.0001 for all groups). While the risk of cancer, particularly HCC, is elevated among people with HBV and HCV infection, the absolute risk remains low. Young people with HCV face a higher mortality risk from continued drug use than from liver damage related to their HCV infection. The influence of IDU in the epidemiology of HCC in New South Wales was possibly reflected in the varying distributions of age and country of birth.

Diss. (sammanfattning) Stockholm : Karolinska institutet, 2006. / Härtill 4 uppsatser.

Thesis (Dr. P.H.)--University of Texas Health Science Center at Houston, School of Public Health, 2007. / "May 2007." Includes bibliographical references.

A infecção pelo vírus da hepatite C (VHC) é uma das mais comuns infecções ao redor do mundo. Aproximadamente, 20% dos pacientes infectados eliminam espontaneamente o vírus, porém a maioria dos indivíduos infectados desenvolve infecção crônica com amplo espectro de lesões hepáticas, desde inflamação leve até cirrose. A resposta imune do hospedeiro exerce grande influência sobre o desfecho da infecção pelo VHC. O objetivo deste trabalho foi analisar a influência dos polimorfismos genéticos de citocinas na susceptibilidade ou persistência da infecção por VHC e no clareamento espontâneo em uma amostra de pacientes da população do Rio de Janeiro (Brasil). Os polimorfismos genéticos das citocinas TNFA (-308), TGFB1 (codon 10 e 25), IL10 (-1082, -592), IL6 (-174) e IFNG (+874) foram analisados por PCR-SSP em 245 pacientes com hepatite C crônica (HCC), 41 pacientes que alcançaram o clareamento viral espontâneo e 189 indivíduos controle saudáveis. Além disso, os polimorfismos próximos ao gene da citocina IL28B (rs12979860, rs12980275 e rs8099917) foram analisados por PCR em tempo real em todos os grupos. O grau de fibrose e inflamação, a resposta ao tratamento e o genótipo do vírus também foram levados em consideração quanto ao desfecho da HCC Os genótipos IL28B rs12979860 CC e CT e rs12980275 AA e AG foram significativamente associados ao clareamento espontâneo e à resposta à terapia anti-viral. Da mesma forma, o alelo C (rs12979860) e o alelo A (rs12980275) foram significativamente maior no grupo Clareamento. O alelo C de IL6 (-174) foi associado com o Clareamento. Nenhuma associação entre as demais citocinas e o desfecho da HCC foi encontrada. O Genótipo TNFA (-308) GG parece estar associado com menor grau de inflamação. Além disso, a etnia auto declarada influencia a distribuição dos polimorfismos em IL6 (-174) e IL28B rs12979860 e rs8099917. Nossas observações indicam que os polimorfismos próximos ao gene da IL28B estão associados com o clareamento viral e resposta ao tratamento na população do Rio de Janeiro. Além disso, nossos resultados podem ser úteis para futuras investigações entre os polimorfismos de citocinas e a infecção por VHC numa população heterogênea como a Brasileira. / Hepatitis C virus infection is one of the most common blood-borne infections worldwide. Approximately, 20% of infected patients successfully eliminate the virus, whereas the majority of patients develop chronic infection with a wide spectrum of liver lesions, ranging from a minimal inflammation to cirrhosis. The host's immune response is an important correlate of HCV infection outcome and disease progression. The aim of this study was to explore the possibility of the inheritance of cytokine gene polymorphisms as a candidate for susceptibility to persistent HCV infection or HCV clearance in a sample of Rio de Janeiro (Brazil) population. Genetic polymorphisms in the cytokines TNFA (-308), TGFB1 (codon 10 and 25), IL10 (-1082, -592), IL6 (-174) and IFNG (+874) were analyzed by polymerase chain reaction-sequence-specific primer (SSP) in 245 chronic hepatitis C (HCC) patients, 41 spontaneous recovery (SR) patients and 189 healthy volunteers. Further, IL28B (rs12979860, rs12980275 and rs8099917) were assessed by real-time PCR in all groups. Liver fibrosis and inflammation staging, response to treatment and virus genotype were also tested to influence in HCV chronic infection. IL28B rs12989760 CC and rs12980275 AA genotypes were significantly associated with spontaneous recovery of HCV infection and response to therapy. Likewise, C allele (rs12979860) and A allele (rs12980275) were also more frequent in SR group, while C allele of IL6 (-174) is associated with persistence to HCC. No association was found between other cytokine gene polymorphism and susceptibility to HCV infection and response to treatment. Multivariate analysis showed male, IL28B rs12979860 CT and TT and TGFB1 (codon 10) TC genotypes to be factors associated with HCC. TNFA (-308) GG genotype seems to be associated with moderate stage of inflammation. Also, ethnicity according self-declared is supposed to influence the distribution IL6 (-174) and IL28B rs12979860 and rs8099917 polymorphisms. These results suggest that the IL28B polymorphisms are associated with spontaneous clearance of HCV and response to therapy in a Brazilian population. Moreover, these results could be useful to further association between cytokine polymorphism and HCV infection outcome in Brazilian admixture population.

Dendrimers are synthetic macromolecules with branches-upon-branches structures, nanoscale dimensions and a high density of surface groups. Presence of multiple cationic sites in dendrimers permits their efficient nucleic acid complexation and cellular internalization through endocytic pathways. PETIM dendrimers of are characterized by tertiary amine branch points, and ether linkages. A third generation PETIM dendrimer, G3(NH2)24, with nitrogen at the core and twenty four peripheral primary amines was synthesized through alternate Michael addition and reduction reactions. The ability of G3(NH2)24 to interact with DNA was ascertained by spectroscopic and bio-physical techniques. These studies established the formation of dendrimer-DNA, and complex formation was also shown to protect the plasmid DNA from nucleases. Toxicity studies in cell culture, as well as, in female Balb/c mice established the non-toxic properties of the dendrimer. G3(NH2)24 was able to mediate efficient transfection in mammalian cells and in vivo. Targeted delivery of small interfering RNA (siRNA) to hepatocytes, in order to combat hepatitis C virus (HCV) infection was undertaken to expand the scope of PETIM dendrimer based gene delivery. Functionalization of the dendrimer periphery with galactose units ensured preferential delivery to the liver through multivalent interactions with the asialoglycoprotein receptors on the liver cell surface. The delivery of siRNA to the perinuclear region, in close proximity to the HCV RNA replication site resulted in ~75% decrease in viral RNA levels in replicon containing cells, as well as, JFH-1 infectious virus systems. The dendrimer-siRNA complexes were preferentially delivered to mice liver and were active in vivo. Physico-chemical studies of the protonation pattern of PETIM dendrimer indicated that the protonation of the dendrimer amines proceeded in a shell-wise pattern from the periphery to the core. The primary amines of the dendrimer as well as the outer shell tertiary amines with pKa values ~7-10 were protonated at physiological pH and were cationic sites for nucleic acid condensation. The inner shell tertiary amines with a pKa of ~4-6 were protonated at endosomal pH and aided ‘endosomal escape’ due to the high buffering capacity of 3.5. Work described in the Thesis establish a new synthetic dendrimer vector, namely, the series of PETIM dendrimers, as a high value gene delivery vector, making in-roads towards pre-clinical and possible clinical trials in future studies.

La découverte d’adjuvants de vaccination est en pleine expansion dans un contexte règlementaire de plus en plus strict. L’objectif de ce travail de thèse a été de proposer un adjuvant hautement caractérisé de la famille de la lysophosphatidylcholine (LPC) pour un développement clinique. Il avait été précédemment montré que la LPC d’oeuf de poule présentait des propriétés adjuvantes in vitro et in Vivo. Cependant, il s’agit d’un mélange hétérogène d’espèces moléculaires de LPC peu exploitable en clinique. Nous avons donc cherché à 1/ cribler in vitro 5 différentes espèces moléculaires de LPC ayant des activités adjuvantes, et 2/ évaluer chez la souris l’aptitude des molécules sélectionnées à induire des réponses humorales et cellulaires.Deux candidats, les LPC C16 :0 et C18 :0, induisent in vitro la maturation de cellules dendritiques humaines caractérisée par l’augmentation de l’expression des marqueurs de surface, la production de chimiokines pro-Th1 et l’engagement vers un profil Th1 de lymphocytes T CD4+. Chez la souris, l’injection i. v. des candidats induit une réponse inflammatoire transitoire et modérée au profil Th2 (IL-5, IL-6). De plus, ces espèces induisen une réponse humorale spécifique contre 3 antigènes viraux après injection s. c. ou i. m. (NS3du VHC, HBsAg du VHB et gp120 du VIH), proche de celle obtenue avec l’alun et à des doses faibles supposées non toxiques. Dans ces modèles, en revanche, les LPC individuelles ne semblent pas induire de réponses cellulaires spécifiques.L’ensemble de ces résultats ouvre d’intéressantes perspectives pour l’utilisation des LPC C16 :0 et C18 :0 en tant qu’adjuvants de vaccination de réponses immunitaires humorales. / The evaluation of new vaccine adjuvants is growing fast in a stringent regulatory environment. The aim of this thesis project was to propose a highly defined adjuvant derived from the lysophosphatidylcholine (LPC) for clinical development. It has been previously shown that an egg-derived LPC has in vitro and in Vivo adjuvant features. However, it is composed of a heterogeneous mixture of molecular species of LPC, thus precluding itsclinical evaluation. Therefore, we decided to 1/ screen in vitro 5 single species of LPC fortheir adjuvant properties, and 2/ evaluate in the mouse model the ability of selected compounds to induce humoral and cellular responses.Two candidates, the C16:0- and C18:0-LPC, induce in vitro maturation of human dendritic cells as defined by an up regulation of the expression of surface markers, production of pro-Th1 chemokines, and engagement of CD4+ T lymphocytes towards a Th1 profile. Inmice, i. v. injection of both candidates triggers a transient and moderate inflammatory response with a Th2 profile (IL-5, IL-6). In addition, these species initiate specific humoral responses against 3 viral antigens following s. c. or i. m. injection (NS3 from HCV, HBsAgfrom HBV and gp120 from HIV), close to what is achieved with alum and at low doses expected to be safe in humans. In these models, however, single LPC do not mediatespecific cellular responses. Over all, these results open interesting perspectives for the single

Introdução: este documento trata de questões relativas à vigilância epidemiológica das hepatites B e C em doadores de sangue que foram notificados no SINAN NET no ano de 2007 no estado do Rio Grande do Sul. Faz parte uma revisão bibliográfica sobre os marcadores sorológicos e técnicas utilizadas pelos laboratórios do banco de sangue e vigilância epidemiológica. Relata as definições e os fluxos estabelecidos pelo PNHV e um artigo que compara os resultados do laboratório do banco de sangue com o laboratório da vigilância epidemiológica. Método: Discute os resultados obtidos neste estudo transversal, com as evidencias levantadas na revisão bibliográfica e busca responder as questões que serviram de estímulo para realização deste estudo. Os resultados concordam? Quanto se gasta para repetir os marcadores? Quanto tempo leva para um doador definir sua situação em relação à doença? Qual a proporção de doadores no quantitativo dos casos notificados de hepatites virais? Resultados: o coeficiente Kappa para o marcador HBsAg foi de 0,74 para o Anti-HBc 0,72 , para HBsAg e Anti-HBc associados foi 0,98 e para o Anti-HCV foi de 0,82. O gasto para repetição destes marcadores foi de R$ 28.956,55. O tempo de espera para o doador definir sua situação em relação à doença foi de uma mediana de 162 dias. A proporção de doadores notificados foi de 7,90%. Conclusão e considerações finais: Os resultados obtidos evidenciam que esta concordância existe, variando de substancial a concordância quase perfeita, para os casos de interesse da vigilância epidemiológica. O tempo de espera evidencia o não atendimento de um critério básico da vigilância epidemiológica, o da oportunidade. A vigilância epidemiológica aceitando o resultado dos laboratórios do banco de sangue como suficientes estará evitando gastos para o sistema de saúde, agilizando o processo de vigilância, aumentando a capacidade operacional do laboratório da vigilância bem como encurtando o tempo de espera do doador para definir sua situação de saúde. / Introduction: This document addresses issues related to epidemiological surveillance of hepatitis B and C in blood donors have been reported in SINAN NET in 2007 in Rio Grande do Sul is composed of a literature review on the serological markers and techniques used by the laboratories of the blood bank and epidemiological surveillance. On definitions and flows down the PNHV and an article comparing the results of laboratory blood bank with laboratory surveillance. Method: Discusses the results of this cross-sectional study, with the evidence raised in the review and seeks to answer the questions that served as a stimulus for this study. The results agree? How much is spent to repeat the markers? How long does it take for a donor set their status in relation to the disease? What proportion of donors in the quantity of reported cases of viral hepatitis? Results: Kappa coefficient for the marker HBsAg was 0.74 to 0.72 Anti-HBc, HBsAg and Anti-HBc was associated with 0.98 and the Anti-HCV was 0.82. Spending for repetition of these markers was $ 28,956.55 real. The waiting time for donors to define their status in relation to the disease was a median of 162 days. The proportion of donors reported was 7.90%. Conclusion and final remarks: The results show that this correlation exists, ranging from substantial to almost perfect agreement, for cases of interest for epidemiological surveillance. The waiting time shows the non-fulfillment of a basic criterion of epidemiological surveillance of opportunity. Epidemiological surveillance accepting the results of laboratory blood bank as insufficient, it will avoid costly to the health system, streamlining the process of monitoring, increasing the operational capacity of the laboratory surveillance as well as shortening the time for a donor to define their health situation.

Objetivo: A vacina inativada contra HVA (Havrix) é altamente eficaz e segura em crianças saudáveis. Não há muitos dados disponíveis na literatura sobre a resposta de crianças imunocomprometidas à essa vacina. O objetivo deste estudo foi avaliar a resposta de pacientes pediátricos portadores de Síndrome de Down e de Hepatopatia Crônica à uma vacina inativada contra Hepatite A, comparando suas respostas com as de crianças saudáveis. Casuística e Métodos: Foi realizado um estudo prospectivo, aberto e controlado com 138 crianças e adolescentes, de 1 a 16 anos, suscetíveis à infecção pelo virus A (anti-HVA negativo). Os indivíduos foram divididos em 3 grupos: Grupo I: portadores de Síndrome de Down (n = 49), Grupo II: Hepatopatas Crônicos (n = 34) e Grupo III: controle, composto por crianças saudáveis (n = 55). Todos os indivíduos recebiam 2 doses, nos meses 0 e 6, da vacina Havrix 720 UE , aplicada intramuscular, no deltóide. Um mês após cada dose da vacina, as crianças e os adolescentes eram submetidas à coleta de sangue para realização de titulação de anticorpos anti-HVA. Resultados: As taxas de soroconversão, após a primeira dose da vacina, no mês 1, foram de 92%, 76% e 94% nos grupos I, II e III, respectivamente. Um mês após a segunda dose, as porcentagens de soroconversão foram de 100% x 97% x 100%, para os grupos, na mesma ordem. As médias geométricas dos títulos de anticorpos anti-HVA foram, na primeira e segunda coletas, de 164,02 e 1719,86 mUI/ml nas crianças com Síndrome de Down, de 107,77 e 812,40 mUI/ml nos cirróticos e de 160,77 e 2344,90 mUI/ml, no grupo controle. O grupo dos pacientes cirróticos apresentou diferença estatisticamente significativa em relação às taxas de soroconversão no primeiro mês, após 1 dose da vacina, e aos títulos de anticorpos anti-HVA no final do estudo, quando comparado aos controles saudáveis. Apenas 14% dos indivíduos vacinados apresentaram sintomas locais, como dor e vermelhidão. Cinco porcento apresentaram sintomas gerais. Não ocorreu nenhum efeito adverso sério ou reação imediata à vacina. Os efeitos adversos diminuíram por ocasião da segunda dose.Conclusões: A vacina inativada Havrix, contra Hepatite A, provoca altas taxas de soroconversão e é altamente segura em pacientes pediátricos portadores de Síndrome de Down e de Cirrose. As crianças e adolescentes com Cirrose respondem à vacina inativada anti-HVA com títulos de anticorpos mais baixos do que as crianças saudáveis e do que as portadoras de Síndrome de Down. / Objective: The inactivated hepatitis A vaccine (Havrix) is highly immunogenic and safe in healthy children. However, data about the response of immunocompromised children to this vaccine are not very frequent in the literature. The objective of this study was to assess the response of pediatric patients with Down syndrome and chronic liver disease to an inactivated hepatitis A vaccine, and to compare their responses to those of healthy children. Patients and Methods: A prospective, open-label, controlled study was performed with 138 children and adolescents susceptible to hepatitis A virus (anti-HAV negative) with ages between 1 and 16 years. Patients were divided into three groups: Group I, Down syndrome patients (n = 49); Group II, patients with chronic liver disease (n = 34); and Group III, healthy children/controls (n = 55). All patients and controls received two intramuscular doses of Havrix 720 UE in the deltoid muscle at months 0 and 6. One month after each dose, patients underwent blood collection for the assessment of anti-HAV titers. Results: Seroconversion rates after the first dose (month 1) were 92%, 76%, and 94% in Groups I, II, and III, respectively; one month after the second dose, these percentages were 100%, 97%, and 100%. Geometric mean titers were 164.02 and 1719.86 mUI/ml in the first and second collections for Down syndrome children; 107.77 and 812.40 mUI/ml for cirrhotic patients; and 160.77 and 2344.90 mUI/ml for controls. The group of cirrhotic patients presented a statistically significant difference in seroconversion rates at month 1, and in anti-HAV titers in the end of the study when compared to healthy controls. Only 14% of the vaccinated individuals presented local symptoms, such as pain and redness; 5% presented general symptoms. No severe adverse effects or immediate reaction to the vaccine were observed. The occurrence of adverse reactions was lower in the application of the second dose. Conclusions: The inactivated hepatitis A vaccine (Havrix) presents high rates of seroconversion and is highly safe in pediatric patients with Down syndrome and cirrhosis. Cirrhotic children and adolescents have responded to the inactivated hepatitis A vaccine with lower antibody titers when compared to healthy children and Down syndrome.

The diploma thesis Infectious diseases of drug users is focused on monitoring the trend in the incidence of selected infectious diseases associated with the drug usage for a certain period of time. I have chosen viral hepatitis B and C for this monitoring because they belong to the most common infections typical for drug addicts at all. The issue of infectious diseases associated with intravenous drug usage is quite extensive therefore I tried to mention the most important information. Transmission of infectious diseases through intravenous drug usage is particularly insidious due to irrelevant length depending on time. The risk on non-compliance of basic hygiene measures is possible after a single application (using a sterile needle and syringe, a separate drug solution etc.). Another serious risk is that the viral hepatitis B and C can pass into the chronic stage, which significantly affects the quality of life and can also significantly reduce it. HIV infection is still incurable so it ends with the early death of the patient. If the syphilis is not treated and passes into the third stage it can ends up fatally. Infectious endocarditis is a serious life-threatening illness if not recognized and treated early. The diploma thesis has theoretical and practical part. In the theoretical part of this thesis I deal with various infectious diseases related to drug usage. I chose the most common disease according to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): viral hepatitis A, B, C, infections transmitted by sexual contact (syphilis, gonorrhea), HIV / AIDS, tuberculosis, infectious endocarditis and infections of the skin and soft tissues. Individual infections are divided into several chapters where the causative agent is described, mode of transmission, clinical picture, disease diagnosis, treatment and epidemiological measures. In the theoretical part I drew inspiration from the literature, internet sources and valid legal legislation. In the practical part I paid attention to the issue of occurrence of viral hepatitis B and C in the Pilsen Region for a certain period of time typical for intravenous drug users and the rest of the population. I compare these figures to the incidence of viral hepatitis in other regions of the Czech Republic for the same years. Data are analysed using quantitative research technique of secondary data analysis. Data are obtained from the information reporting system and records of transmissible diseases EPIDAT and from annual reports of the Czech Republic. The diploma thesis has one objective: to characterize and compare the trends of selected infectious diseases among drug users and the general population of the Pilsen Region in 2003-2011. Four hypotheses were defined: H1: The incidence of infectious diseases among drug users has been growing. H2: The frequency of infectious diseases among drug users in the Pilsen Region in the period 2003-2011 is comparable to the incidence of infectious diseases among drug users in the Czech Republic in the same time period. H3: The sickness rate of viral hepatitis B among drug users in the Pilsen Region in the period 2003-2011 is statistically more significant than among the general population of the Pilsen Region in the same time period. H4: The sickness rate of viral hepatitis C among drug users in the Pilsen Region in the period 2003-2011 is statistically more significant than among the general population of the Pilsen Region in the same time period. Due to lack of information in 2002, the objective of this diploma thesis and individual hypotheses had to be modified. Therefore the period relates to the year 2003-2011. Individual hypotheses were statistically tested to determine the statistical significance. The first and second hypothesis was refuted. A third hypothesis and fourth hypothesis was confirmed.

A infecção pelo vírus da hepatite C (VHC) é uma das mais comuns infecções ao redor do mundo. Aproximadamente, 20% dos pacientes infectados eliminam espontaneamente o vírus, porém a maioria dos indivíduos infectados desenvolve infecção crônica com amplo espectro de lesões hepáticas, desde inflamação leve até cirrose. A resposta imune do hospedeiro exerce grande influência sobre o desfecho da infecção pelo VHC. O objetivo deste trabalho foi analisar a influência dos polimorfismos genéticos de citocinas na susceptibilidade ou persistência da infecção por VHC e no clareamento espontâneo em uma amostra de pacientes da população do Rio de Janeiro (Brasil). Os polimorfismos genéticos das citocinas TNFA (-308), TGFB1 (codon 10 e 25), IL10 (-1082, -592), IL6 (-174) e IFNG (+874) foram analisados por PCR-SSP em 245 pacientes com hepatite C crônica (HCC), 41 pacientes que alcançaram o clareamento viral espontâneo e 189 indivíduos controle saudáveis. Além disso, os polimorfismos próximos ao gene da citocina IL28B (rs12979860, rs12980275 e rs8099917) foram analisados por PCR em tempo real em todos os grupos. O grau de fibrose e inflamação, a resposta ao tratamento e o genótipo do vírus também foram levados em consideração quanto ao desfecho da HCC Os genótipos IL28B rs12979860 CC e CT e rs12980275 AA e AG foram significativamente associados ao clareamento espontâneo e à resposta à terapia anti-viral. Da mesma forma, o alelo C (rs12979860) e o alelo A (rs12980275) foram significativamente maior no grupo Clareamento. O alelo C de IL6 (-174) foi associado com o Clareamento. Nenhuma associação entre as demais citocinas e o desfecho da HCC foi encontrada. O Genótipo TNFA (-308) GG parece estar associado com menor grau de inflamação. Além disso, a etnia auto declarada influencia a distribuição dos polimorfismos em IL6 (-174) e IL28B rs12979860 e rs8099917. Nossas observações indicam que os polimorfismos próximos ao gene da IL28B estão associados com o clareamento viral e resposta ao tratamento na população do Rio de Janeiro. Além disso, nossos resultados podem ser úteis para futuras investigações entre os polimorfismos de citocinas e a infecção por VHC numa população heterogênea como a Brasileira. / Hepatitis C virus infection is one of the most common blood-borne infections worldwide. Approximately, 20% of infected patients successfully eliminate the virus, whereas the majority of patients develop chronic infection with a wide spectrum of liver lesions, ranging from a minimal inflammation to cirrhosis. The host's immune response is an important correlate of HCV infection outcome and disease progression. The aim of this study was to explore the possibility of the inheritance of cytokine gene polymorphisms as a candidate for susceptibility to persistent HCV infection or HCV clearance in a sample of Rio de Janeiro (Brazil) population. Genetic polymorphisms in the cytokines TNFA (-308), TGFB1 (codon 10 and 25), IL10 (-1082, -592), IL6 (-174) and IFNG (+874) were analyzed by polymerase chain reaction-sequence-specific primer (SSP) in 245 chronic hepatitis C (HCC) patients, 41 spontaneous recovery (SR) patients and 189 healthy volunteers. Further, IL28B (rs12979860, rs12980275 and rs8099917) were assessed by real-time PCR in all groups. Liver fibrosis and inflammation staging, response to treatment and virus genotype were also tested to influence in HCV chronic infection. IL28B rs12989760 CC and rs12980275 AA genotypes were significantly associated with spontaneous recovery of HCV infection and response to therapy. Likewise, C allele (rs12979860) and A allele (rs12980275) were also more frequent in SR group, while C allele of IL6 (-174) is associated with persistence to HCC. No association was found between other cytokine gene polymorphism and susceptibility to HCV infection and response to treatment. Multivariate analysis showed male, IL28B rs12979860 CT and TT and TGFB1 (codon 10) TC genotypes to be factors associated with HCC. TNFA (-308) GG genotype seems to be associated with moderate stage of inflammation. Also, ethnicity according self-declared is supposed to influence the distribution IL6 (-174) and IL28B rs12979860 and rs8099917 polymorphisms. These results suggest that the IL28B polymorphisms are associated with spontaneous clearance of HCV and response to therapy in a Brazilian population. Moreover, these results could be useful to further association between cytokine polymorphism and HCV infection outcome in Brazilian admixture population.